Lowry Curley

Orchid Cellmark, Inc. provides DNA testing services. It generates genetic profile information by analysing an organism's unique genetic identity. The firm also offers non-DNA forensic laboratory services. The company was founded on March 8, 1995 and is headquartered in Princeton, NJ.

Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom.

Conductor, Inc. is a content technology company, which engages in the provision of search engine optimization measurement tools. It offerssupports and services including site audits, site migrations, content strategy. The company was founded by Richard Safran, Selina Eizik, Seth Besmertnik and Jeremy Duboys in 2005 and is headquartered in New York, NY.

Bioceptive, Inc. develops medical devices for gynecological procedures. Its products includes, intrauterine device (IUD) inserter that vastly simplifies the insertion procedure, while reducing the complications inherent with current insertion techniques. The company was founded by Shuchi Khurana and Benjamin D. Cappiello in September 2010 and is ehadquartered in New Orleans, LA.

KeyMe LLC provides security software applications. It offers an application that allows users to store, share, and duplicate their physical keys based on a digital scan that is stored in the cloud. The firm's KeyMe app, helps users to secure mail order keys by using a variety of key designs including sports, charity, designer, and bottle opener key. The company was founded by Gregory A. Marsh and Kris Borer in 2012 and is headquartered in New York, NY.

Battery Ventures is a private equity and venture capital firm is founded in 1983. The firm is headquartered in Boston, Massachusetts.

Part of GSK Plc, Smithkline Beckman Corp is a company that manufactures pharmaceutical products. The company is based in Philadelphia, PA. Smithkline Beckman was acquired by Smithkline Beecham Plc on July 27, 1989 for $16,082.37 million.

EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA.

MicroBiome Therapeutics LLC develops drug therapies for metabolic diseases. Its microbiome modulators are designed to augment the growth of certain desirable bacterial strains and discourage the growth of others. The company was founded by John B. Elstrott and Dale R. Pfost in 2009 and is headquartered in New Orleans, LA.

Biopticon Corp. operates as a developer, manufacturer, and marketer of measurement and data management systems for pre clinical animal studies. It offers Tumorimager 2, Tumorimager, and Tumormanager. The company was founded by Ibrahim Cem Girit in 2004 and is headquartered in Princeton, NJ.

Nicoventures Trading Ltd. researches, develops, manufactures and delivers tobacco harm reduction products and services. The firm provides innovative and sustainable solutions to global problems arising from smoking and smoking-related illnesses. The company develops ortfolio of products and services focused on smoking cessation and harm reduction, including user-friendly nicotine delivery systems and patient-focused smoking cessation and support services. The company was founded by Christopher John Lord and David Thomas Newns in September 2008 and is headquartered in Manchester, the United Kingdom.

Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX.

Lodo Therapeutics Corp. engages in the development of novel therapeutics from its metagenomics-based small molecule discovery platform. Its Lodo platform leverages breakthroughs in next-generation sequencing (NGS), artificial intelligence (AI), and machine learning (ML), along with advances in synthetic biology and automation. The company was founded by Sean Brady and David L. Pompliano and is headquartered in New York, NY.

Prosus Ventures (Prosus) is a venture capital subsidiary of Naspers Ltd founded in 2015. The firm is headquartered in Cape Town, South Africa.

SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA.

Bioelectronica Corp. is a research-stage biotechnology company that specializes in building intelligent, digital tools for drug discovery, cell screening, and cell sorting. The company is based in Reno, NV. The company's platform technology combines computer vision, biochemical reagents, and consumer electronics to accelerate discovery. Bioelectronica was founded by Roger Chen and Jonathan Hull.

Benson Capital Partners (Benson Capital) is a private equity/venture capital firm founded in 2019 by Gayle Benson. The firm is headquartered in New Orleans, Louisiana.

Ancilia Biosciences, Inc. is an American company that is developing virus-resistant live bacterial biotherapeutics to alter the gut microbiome and treat disease. Ancilia is based in the United States, and its founders and advisers include key scientific leaders across CRISPR and the virome. Ancilia's proprietary platform is being developed as an essential enabling technology that characterizes viral phages and leverages the natural function of CRISPR to produce a new class of live biotherapeutics with engineered immunity to key viral pathogens. The company has demonstrated proof of principle and filed key patents for the technology. The company was founded to overcome a potential obstacle to the success of LBPs, which is their failure to address the role of predatory viral phages in causing disease and limiting the ability of LBPs to engraft in the gut. The company was founded by Alexandra Sakatos, who has been the CEO since incorporation.